US PATENT SUBCLASS 530 / 387.3
.~.~.~.~ Chimeric, mutated, or recombined hybrid (e.g., bifunctional, bispecific, rodent-human chimeric, single chain, rFv, immunoglobulin fusion protein, etc.)

Current as of: June, 1999
Click HD for Main Headings
Click for All Classes

Internet Version by PATENTEC © 1999      Terms of Use


530 /   HD   CHEMISTRY: NATURAL RESINS OR DERIVATIVES; PEPTIDES OR PROTEINS; LIGNINS OR REACTION PRODUCTS THEREOF

350  DF  PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES {14}
380  DF  .~ Blood proteins or globulins, e.g., proteoglycans, platelet factor 4, thyroglobulin, thyroxine, etc. {3}
386  DF  .~.~ Globulins {4}
387.1  DF  .~.~.~ Immunoglobulin, antibody, or fragment thereof, other than immunoglobulin antibody, or fragment thereof that is conjugated or absorbed {9}
387.3.~.~.~.~ Chimeric, mutated, or recombined hybrid (e.g., bifunctional, bispecific, rodent-human chimeric, single chain, rFv, immunoglobulin fusion protein, etc.)

DEFINITION

Classification: 530/387.3

Chimeric, mutated, or recombined hybrid (e.g., bifunctional, bispecific, rodent-human chimeric, single chain, rFv, immunoglobulin fusion protein, etc.):

(under subclass 387.1) Subject matter involving an antibody or antibody fragment altered with respect to its amino acid sequence; with respect to its composition of heavy and light chains or immunoglobulin domains; or with respect to its glycosylation, as compared with that found in nature; or involving an antibody or antibody fragment fused to a nonimmunoglobulin amino acid sequence.

(1) Note. Chimeric and recombined hybrid antibodies comprise amino acid sequences derived from two or more nonidentical immunoglobulin mole-cules--e.g., interspecies combinations, etc.

(2) Note. Chimeric, mutated, and recombined hybrid antibodies may be made either by chemical alteration of existing antibodies or by the expression of cloned genes for altered or recombined antibodies. Glycosylation of the antibody molecules may be altered when expressed in host cells of species other than their own.

(3) Note. It is suggested that the patents of this subclass be cross-referenced to the appropriate subclass(es) that provide for the binding specificity of these antibodies, if disclosed.